GUJARAT THEMIS BIOSYN LTD. - 506879 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on December 21, 2023 for Pharmaceuticals Business Group (India) Ltd GUJARAT THEMIS BIOSYN LTD. - 506879 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on December 20, 2023 for Pharmaceuticals Business Group (India) Ltd GUJARAT THEMIS BIOSYN LTD. - 506879 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Please find our intimation on the captioned matter GUJARAT THEMIS BIOSYN LTD. - 506879 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Please find our intimation on the captioned subject GUJARAT THEMIS BIOSYN LTD. - 506879 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Please find our intimation on the captioned subject and for publication of unaudited financial results for the quarter and half year ended 30th September 2023 GUJARAT THEMIS BIOSYN LTD. - 506879 - Announcement under Regulation 30 (LODR)-Investor Presentation
Please find our intimation on the captioned subject GUJARAT THEMIS BIOSYN LTD. - 506879 - Financial Results For The Quarter And Half Year Ended 30Th September 2023
Please find financial results along with outcome of board meeting of the Company held on 4th November 2023 GUJARAT THEMIS BIOSYN LTD. - 506879 - Board Meeting Outcome for Outcome Of Board Meeting Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('Listing Regulations')
Pursuant to Regulation 30 of the Listing Regulations, this is to inform you that the Board of Directors of the Company, at its meeting held today i.e. on Saturday, 4th November, 2023, has inter-alia approved the following: a) The Unaudited Standalone Financial Results for the Quarter and Half year ended 30th September, 2023. A copy of Unaudited Standalone Financial Results for the Quarter and Half year ended 30th September, 2023 together with Limited Review Report is enclosed herewith. b) the proposal to enter into Master Service Agreement with its Related Party, viz. Themis Medicare Limited. The details required as per SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 read with Regulation 30A of the Listing Regulations are enclosed as Annexure - I. This may be taken as compliance under the Listing Regulations. GUJARAT THEMIS BIOSYN LTD. - 506879 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Please find our intimation on the captioned matter GUJARAT THEMIS BIOSYN LTD. - 506879 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Please find our intimation under Regulation 39(3) of SEBI (LODR) Regulations, 2015